Role of oral tetracyclines in preventing acneiform rash in patients with non–small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review

Oral tetracyclines appear to reduce the incidence of all-grade acneiform rash or, alternatively, to decrease the incidence of high-grade rash. Preventive treatment for acneiform rash at the initiation of epidermal growth factor receptor tyrosine kinase inhibitor therapy should therefore be considered. Further controlled trials are needed to confirm the efficacy of oral tetracyclines in preventing acneiform rash.